Literature DB >> 28817419

The Association of Fat and Lean Tissue With Whole Body and Spine Bone Mineral Density Is Modified by HIV Status and Sex in Children and Youth.

Denise L Jacobson, Jane C Lindsey, Brent A Coull, Kathleen Mulligan, Priya Bhagwat, Grace M Aldrovandi.   

Abstract

BACKGROUND: HIV-infected (HIV-pos) male children/youth showed lower bone mineral density at sexual maturity than HIV-uninfected (HIV-neg) females. It is not known whether complications of HIV disease, including abnormal body fat distribution, contribute to lower bone accrual in male HIV-pos adolescents.
METHODS: In a cross-sectional study, we evaluated the relationship between body composition (fat and lean mass) and bone mass in HIV-pos and HIV-neg children/youth and determined if it is modified by HIV status and sex. We used generalized estimating equations to simultaneously model the effect of fat/lean mass on multiple bone outcomes, including total body bone mineral density and bone mineral content and spine bone mineral density. We evaluated effect modification by HIV and sex.
RESULTS: The analysis cohort consisted of 143 HIV-neg and 236 HIV-pos, of whom 55% were black non-Hispanic and 53% were male. Ages ranged from 7 to < 25 years. Half of the children/youth were at Tanner stage 1 and 20% at Tanner 5. Fat mass was more strongly positively correlated with bone mass in HIV-neg than HIV-pos children/youth and these relationships were more evident for total body bone than spine outcomes. Within HIV strata, fat mass and bone were more correlated in female than male children/youth. The relationship between lean mass and bone varied by sex, but not by HIV status.
CONCLUSIONS: HIV disease diminishes the positive relationship of greater fat mass on bone mass in children/youth. Disruptions in body fat distribution, which are common in HIV disease, may have an impact on bone accretion during pubertal development.

Entities:  

Mesh:

Year:  2018        PMID: 28817419      PMCID: PMC5725259          DOI: 10.1097/INF.0000000000001715

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  40 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

Review 2.  Adolescent bone health.

Authors:  Keith J Loud; Catherine M Gordon
Journal:  Arch Pediatr Adolesc Med       Date:  2006-10

3.  Association of lean and fat body mass, bone biomarkers and gonadal steroids with bone mass during pre- and midpuberty.

Authors:  Violetta Csakvary; Eva Erhardt; Peter Vargha; Gyorgy Oroszlan; Tamas Bodecs; Dora Torok; Erzsebet Toldy; Gabor L Kovacs
Journal:  Horm Res Paediatr       Date:  2012-11-09       Impact factor: 2.852

Review 4.  Bone as an endocrine organ.

Authors:  Anyonya R Guntur; Clifford J Rosen
Journal:  Endocr Pract       Date:  2012 Sep-Oct       Impact factor: 3.443

5.  Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

Authors:  Michael P Dubé; Robert A Parker; Pablo Tebas; Steven K Grinspoon; Robert A Zackin; Gregory K Robbins; Ronenn Roubenoff; Robert W Shafer; David A Wininger; William A Meyer; Sally W Snyder; Kathleen Mulligan
Journal:  AIDS       Date:  2005-11-04       Impact factor: 4.177

6.  Age at onset of puberty predicts bone mass in young adulthood.

Authors:  Vicente Gilsanz; James Chalfant; Heidi Kalkwarf; Babette Zemel; Joan Lappe; Sharon Oberfield; John Shepherd; Tishya Wren; Karen Winer
Journal:  J Pediatr       Date:  2010-08-24       Impact factor: 4.406

7.  Morphologic and metabolic abnormalities in vertically HIV-infected children and youth.

Authors:  Grace M Aldrovandi; Jane C Lindsey; Denise L Jacobson; Amanda Zadzilka; Elizabeth Sheeran; Jack Moye; Peggy Borum; William A Meyer; Dana S Hardin; Kathleen Mulligan
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

Review 8.  A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms.

Authors:  Cyrille B Confavreux; Robert L Levine; Gerard Karsenty
Journal:  Mol Cell Endocrinol       Date:  2009-04-17       Impact factor: 4.102

Review 9.  The Official Positions of the International Society for Clinical Densitometry: body composition analysis reporting.

Authors:  Steven Petak; Carmen G Barbu; Elaine W Yu; Roger Fielding; Kathleen Mulligan; Brian Sabowitz; Chih-Hsing Wu; John A Shepherd
Journal:  J Clin Densitom       Date:  2013 Oct-Dec       Impact factor: 2.617

10.  Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045.

Authors:  Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

View more
  3 in total

Review 1.  Noncommunicable diseases in adolescents with perinatally acquired HIV-1 infection in high-income and low-income settings.

Authors:  Steve Innes; Kunjal Patel
Journal:  Curr Opin HIV AIDS       Date:  2018-05       Impact factor: 4.283

2.  Gut Dysfunction Markers Are Associated With Body Composition in Youth Living With Perinatally Acquired Human Immunodeficiency Virus.

Authors:  Sahera Dirajlal-Fargo; Denise L Jacobson; Wendy Yu; Ayesha Mirza; Mitchell E Geffner; Jennifer Jao; Grace A McComsey
Journal:  Clin Infect Dis       Date:  2022-09-29       Impact factor: 20.999

Review 3.  Cardiometabolic Complications in Youth With Perinatally Acquired HIV in the Era of Antiretroviral Therapy.

Authors:  Sahera Dirajlal-Fargo; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2021-10-15       Impact factor: 5.495

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.